盐酸右美托咪定鼻喷雾剂在口腔种植手术中的应用——一项多中心前瞻性随机对照研究

注册号:

Registration number:

ChiCTR2500097744 

最近更新日期:

Date of Last Refreshed on:

2025-02-25 11:09:02 

注册时间:

Date of Registration:

2025-02-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

盐酸右美托咪定鼻喷雾剂在口腔种植手术中的应用——一项多中心前瞻性随机对照研究

Public title:

Application of dexmedetomidine hydrochloride nasal spray in oral implant surgery ——a multicenter prospective randomized controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

盐酸右美托咪定鼻喷雾剂在口腔种植手术中的应用——一项多中心前瞻性随机对照研究

Scientific title:

Application of dexmedetomidine hydrochloride nasal spray in oral implant surgery ——a multicenter prospective randomized controlled study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴雨佳 

研究负责人:

吴雨佳 

Applicant:

Yujia Wu 

Study leader:

Yujia Wu 

申请注册联系人电话:

Applicant telephone:

+86 13996198119

研究负责人电话:

Study leader's
telephone:

+86 23 88860192

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

500324@hospital.cqmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

500324@hospital.cqmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆医科大学附属口腔医院麻醉科

研究负责人通讯地址:

重庆市渝北区松石北路426号

Applicant address:

Department of Anesthesiology, Affiliated Stomatological Hospital, Chongqing Medical University

Study leader's address:

No. 426 Songshi North Road, Yubei District, Chongqing City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属口腔医院

Applicant's institution:

Stomatological Hospital of Chongqing Medical University,Chongqing,China

研究负责人所在单位:

重庆医科大学附属口腔医院

Affiliation of the Leader:

Stomatological Hospital of Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024年伦审(129)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属口腔医院伦理委员会

Name of the ethic committee:

Research Ethics Committee The Affiliated Hospital of Stomatology , Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-10-28 00:00:00

伦理委员会联系人:

李海东

Contact Name of the ethic committee:

Haidong Li

伦理委员会联系地址:

重庆市渝北区松石北路426号

Contact Address of the ethic committee:

No. 426 Songshi North Road, Yubei District, Chongqing City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 88602305

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1371170054@qq.com

研究实施负责(组长)单位:

重庆医科大学附属口腔医院

Primary sponsor:

Stomatological Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝北区松石北路426号

Primary sponsor's address:

No. 426 Songshi North Road, Yubei District, Chongqing City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属口腔医院

具体地址:

重庆市渝北区松石北路426号

Institution
hospital:

Stomatological Hospital of Chongqing Medical University

Address:

No. 426 Songshi North Road, Yubei District, Chongqing City

经费或物资来源:

上海恒瑞医药有限公司

Source(s) of funding:

Shanghai Hengrui national multi-center

研究疾病:

牙科焦虑症  

Target disease:

Dental anxiety

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.主要目的 通过多中心前瞻性随机对照研究进行设计,以不同剂量的盐酸右美托咪定鼻喷剂和常规医疗组为对照,观察患者给药后镇静镇痛效果及不良反应,评估盐酸右美托咪定鼻喷剂在口腔种植手术中的有效性和安全性。 2.次要目的 通过比较不同剂量盐酸右美托咪定鼻喷剂的镇静起效率、镇静起效时间、改良警觉/镇静观察评估量表(Modified Observer’s Assessment of Alertness/Sedation Scale,MOAA/S)评分、视觉模拟评分量表(Visual Analogue Scale/Score,VAS)评分、离院评分及时间、术后不良反应的发生等,筛选口腔种植手术镇静镇痛使用盐酸右美托咪定鼻喷剂的最优剂量,从而为口腔种植手术应用盐酸右美托咪定鼻喷剂提供参考。  

Objectives of Study:

Main objective: multicenter prospective randomized controlled study, with different doses of dexmedetomidine hydrochloride nasal spray and conventional medical groups, observe the analgesic effect and adverse effects after patient administration, and evaluate the effectiveness and safety of dexmedetomidine hydrochloride nasal spray in oral implant surgery. Secondary objective: To compare the efficiency of sedative onset, time of onset of sedative, and observed assessment scale at different doses of dexmedetomidine hydrochloride (Modified Observer's Assessment of Alertness / Sedation Scale, MOAA / S) score, visual analogue rating scale (Visual Analogue Scale / Score, VAS) score, departure score and time, occurrence of postoperative adverse reactions, To screen the optimal dose of dexmedetomidine hydrochloride nasal spray for oral implant surgery, thus providing a reference for the application of dexmedetomidine hydrochloride nasal spray in oral implant surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.术前表现为积极合作,无焦虑或血压>180/100mmHg的患者;
2.不适合鼻喷给药的患者,如有鼻塞、严重鼻炎、鼻腔畸形等;
3.脑瘫、自闭症或其他精神病史,正在使用精神类药物;
4.近期饮酒,服用其他药物,特别是选择性α2-肾上腺素受体激动剂或拮抗剂、镇静催眠药、两性霉素B、阿片类镇痛药;
5.既往病史中已知心肌梗死、不稳定心绞痛、严重心律失常、心功能不全的患者;
6.已知对药物过敏或药物中其他成分过敏;
7.任何原因不能配合研究;

Exclusion criteria:

1. Preoperative patients showed active cooperation, without anxiety or blood pressure> 180 / 100mmHg; 2. Patients not suitable for nasal spray administration, such as nasal congestion, severe rhinitis, nasal deformity, etc; 3. History of cerebral palsy, autism or other mental illness, using psychiatric medication; 4. Recent alcohol consumption, taking other drugs, especially selective α 2-adrenoceptor agonists or antagonists, sedative hypnotics, amphotericin B, opioid analgesics; 5. Patients with a known past medical history of myocardial infarction, unstable angina pectoris, severe arrhythmia, and cardiac insufficiency; 6. Known allergy to drugs or other ingredients in the drug; 7. Can not cooperate with the study for any reason;

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-02-25 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

常规医疗组

样本量:

117

Group:

Routine medical group

Sample size:

干预措施:

干预措施代码:

Intervention:

no

Intervention code:

组别:

低剂量干预组

样本量:

117

Group:

Low-dose intervention group

Sample size:

干预措施:

盐酸右美托咪定鼻喷

干预措施代码:

Intervention:

Dexmedetomidine hydrochloride nasal spray

Intervention code:

组别:

高剂量干预组

样本量:

117

Group:

High-dose intervention group

Sample size:

干预措施:

盐酸右美托咪定鼻喷

干预措施代码:

Intervention:

Dexmedetomidine hydrochloride nasal spray

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属口腔医院 

单位级别:

三级甲等 

Institution
hospital:

Stomatological Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

烟台市口腔医院 

单位级别:

三级甲等 

Institution
hospital:

Yantai Stomatological Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学口腔医院 

单位级别:

三级甲等 

Institution
hospital:

Peking University Hospital of Stomatology

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学口腔医院 

单位级别:

三级甲等 

Institution
hospital:

Hospital of Stomatology Xi‘an jiaotong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

青岛市市立医院 

单位级别:

三级甲等 

Institution
hospital:

Qingdao Municipal Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山西 

市(区县):

 

Country:

China

Province:

Shanxi

City:

单位(医院):

山西医科大学口腔医院(山西省口腔医院) 

单位级别:

三级甲等 

Institution
hospital:

Stomatological Hospital of Shanxi Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjing

City:

单位(医院):

天津医科大学口腔医院 

单位级别:

三级甲等 

Institution
hospital:

Hospital of Stomatology, Tianjin Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

四川大学华西口腔医院 

单位级别:

三级甲等 

Institution
hospital:

West China Hospital of Stomatology, Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

南方医科大学口腔医院(广东省口腔医院,广东省牙病防治指导中心) 

单位级别:

三级甲等 

Institution
hospital:

Stomatological Hospital of Southern Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

郑州大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Zhengzhou University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市口腔医院 

单位级别:

无 

Institution
hospital:

Shenzhen Stomatological Hospital

Level of the institution:

N/A

国家:

中国

省(直辖市):

安徽 

市(区县):

 

Country:

China

Province:

Anhui

City:

单位(医院):

中国科学技术大学附属第一医院(安徽省立医院) 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

牙科焦虑评分

指标类型:

主要指标

Outcome:

Dental Anxiety Score

Type:

Primary indicator

测量时间点:

术前和术后

测量方法:

改良版牙科焦虑量表

Measure time point of outcome:

Preoperative and postoperative

Measure method:

Modified dental Anxiety Scale,MDAS

指标中文名:

患者满意度调查

指标类型:

次要指标

Outcome:

Patient Satisfaction Survey

Type:

Secondary indicator

测量时间点:

术后

测量方法:

满意度评分,最高评分为10分,(0-3)差,(4-7)不错,(8-10)良好。

Measure time point of outcome:

postoperative

Measure method:

Satisfaction Rating, the highest score was 10, (0-3) poor, (4-7) good, (8-10) perfect.

指标中文名:

不良反应

指标类型:

主要指标

Outcome:

Adverse reactions

Type:

Primary indicator

测量时间点:

术中、术后

测量方法:

术中观察及术后随访

Measure time point of outcome:

Intraoperative, postoperative

Measure method:

Intraoperative observation and postoperative follow-up

指标中文名:

医生满意度调查

指标类型:

次要指标

Outcome:

Doctor Satisfaction Survey

Type:

Secondary indicator

测量时间点:

术后

测量方法:

满意度评分,最高评分为10分,(0-3)差,(4-7)不错,(8-10)良好。

Measure time point of outcome:

postoperative

Measure method:

Satisfaction Rating, the highest score was 10, (0-3) poor, (4-7) good, (8-10) perfect.

指标中文名:

患者基础信息

指标类型:

次要指标

Outcome:

Basic patient information

Type:

Secondary indicator

测量时间点:

术前

测量方法:

术前访视,包括性别、年龄、身高、体重、BMI、ASA分级、Mallampati分级、有无打鼾;采集患者病史,包括有无睡眠呼吸暂停综合征、手术史、既往史、过敏史等

Measure time point of outcome:

Preoperative

Measure method:

Preoperative visit, Including gender, age, height, weight, BMI, ASA classification, Mallampati classification, presence or absence of snoring;collect the patient's medical history, including sleep apnea syndrome, surgical history, past history, allergy history, etc

指标中文名:

镇静评分

指标类型:

主要指标

Outcome:

Sedation Score

Type:

Primary indicator

测量时间点:

给药后每5分钟测试一次

测量方法:

改良警觉/镇静观察评估量表

Measure time point of outcome:

Test every 5 minutes after administration

Measure method:

Modified Observer’s Assessment of Alertness/Sedation Scale,MOAA/S

指标中文名:

视觉模拟评分

指标类型:

主要指标

Outcome:

Visual Analogue Score

Type:

Primary indicator

测量时间点:

术后

测量方法:

视觉模拟评分量表

Measure time point of outcome:

postoperative

Measure method:

Visual Analogue Scale

指标中文名:

离院评分

指标类型:

主要指标

Outcome:

Discharge Score

Type:

Primary indicator

测量时间点:

术后30min

测量方法:

改良Aldrete离院评分标准

Measure time point of outcome:

30 minutes postoperative

Measure method:

The Modified Aldrete scoring system

指标中文名:

基础生命体征

指标类型:

主要指标

Outcome:

Basic vital signs

Type:

Primary indicator

测量时间点:

术前、给药后至离院时每5分钟测一次

测量方法:

监护仪采集

Measure time point of outcome:

Preoperative, every 5 minutes after administration until discharge.

Measure method:

Monitor acquisition

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由中心随机人员通过随机数字生成器给合格的受试者分配一个唯一的随机数,随机分配按调查地点分层进行。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random personnel from the center assign a unique random number to eligible subjects using a random number generator, with randomization stratified by survey location.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

数据所在网址: http://www.91trial.com/User 时间:2025-12-31

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The URL where the data is located: http://www.91trial.com/User Time: 2025-12-31

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form and Electronic data capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-02-25 11:07:41